Table 3.
Associations between genotypes and concurrent chemoradiotherapy-induced toxicities
| Toxic reactions | SNP | Genotypes | Toxicity grade | OR (95% CI) | P a | |
|---|---|---|---|---|---|---|
| Dermatitis | Grade ≤ 2 N (%) | Grade > 2 N (%) | ||||
| rs1829346 | CC | 219 (48.2) | 21 (41.2) | 1.00 (reference) | ||
| CA | 198 (43.6) | 21 (41.2) | 1.127 (0.597-2.130) | 0.712 | ||
| AA | 37 (8.1) | 9 (17.6) | 2.641 (1.118–6.243) | 0.027 | ||
| AA + CA vs CC | 1.407 (0.767–2.584) | 0.270 | ||||
| AA vs CA + CC | 2.492 (1.121–5.540) | 0.025 | ||||
| rs36080650 | TT | 220 (48.5) | 21 (41.2) | 1.00 (reference) | ||
| CT | 198 (43.6) | 21 (41.2) | 1.130 (0.598–2.135) | 0.706 | ||
| CC | 36 (7.9) | 9 (17.6) | 2.700 (1.141–6.386) | 0.024 | ||
| CC + CT vs TT | 1.414 (0.770–2.595) | 0.264 | ||||
| CC vs CT + TT | 2.544 (1.143–5.662) | 0.022 | ||||
| Neutropenia | Grade ≤ 2 N (%) | Grade > 2 N (%) | ||||
| rs2027701 | AA | 134 (32.6) | 40 (42.6) | 1.00 (reference) | ||
| GA | 205 (49.9) | 42 (44.7) | 0.545 (0.319–0.930) | 0.026 | ||
| GG | 70 (17.0) | 11 (11.7) | 0.378 (0.171–0.836) | 0.016 | ||
| GG + GA vs AA | 0.503 (0.303–0.835) | 0.008 | ||||
| GG vs GA + AA | 0.550 (0.264–1.146) | 0.110 | ||||
| rs73594404 | GG | 374 (91.0) | 79 (84.0) | 1.00 (reference) | ||
| GA | 36 (8.8) | 14 (14.9) | 2.118 (1.011–4.440) | 0.047 | ||
| AA | 1 (0.2) | 1 (1.1) | 3.484 (0.128–95.079) | 0.459 | ||
| AA + GA vs GG | 2.164 (1.049–4.464) | 0.037 | ||||
| AA vs GA + GG | 3.260 (0.121–87.981) | 0.482 | ||||
| rs1059698 | AA | 173 (42.1) | 50 (53.2) | 1.00 (reference) | ||
| CA | 185 (45.0) | 37 (39.4) | 0.780 (0.469–1.295) | 0.336 | ||
| CC | 53 (12.9) | 7 (7.4) | 0.395 (0.161–0.971) | 0.043 | ||
| CC + CA vs AA | 0.660 (0.408–1.070) | 0.092 | ||||
| CC vs CA + AA | 0.443 (0.185–1.058) | 0.067 | ||||
| Anemia | Grade ≤ 0 N (%) | Grade > 0 N (%) | ||||
| rs10132552 | TT | 141 (49.0) | 110 (50.7) | 1.00 (reference) | ||
| CT | 129 (44.8) | 79 (36.4) | 0.764 (0.500–1.169) | 0.215 | ||
| CC | 14 (4.9) | 23 (10.6) | 2.653 (1.172–6.008) | 0.019 | ||
| CC + CT vs TT | 0.929 (0.618–1.398) | 0.725 | ||||
| CC vs CT + TT | 3.001 (1.355–6.646) | 0.007 | ||||
| rs73594404 | GG | 263 (91.3) | 190 (87.6) | 1.00 (reference) | ||
| GA | 25 (8.7) | 25 (11.5) | 2.109 (1.062–4.188) | 0.033 | ||
| AA | 0 (0) | 2 (0.9) | NA | NA | ||
| AA + GA vs GG | 2.239 (1.138–4.405) | 0.020 | ||||
| AA vs GA + GG | NA | NA | ||||
| Myelosuppression | Grade ≤ 2 N (%) | Grade > 2 N (%) | ||||
| rs1059698 | AA | 161 (41.9) | 62 (51.2) | 1.00 (reference) | ||
| CA | 172 (44.8) | 50 (41.3) | 0.810 (0.510–1.287) | 0.373 | ||
| CC | 51 (13.3) | 9 (7.4) | 0.407 (0.180–0.920) | 0.031 | ||
| CC + CA vs AA | 0.708 (0.456–1.098) | 0.123 | ||||
| CC vs CA + AA | 0.449 (0.204–0.987) | 0.046 | ||||
Abbreviations: CI, confidence interval; OR, odds ratio.
P a values were calculated with adjustment for age, sex, BMI, smoking status, drinking status, histological type, clinical stage, T-staging, N-staging, Induction chemotherapy regimens, concurrent chemoradiotherapy regimen, irradiation dose.
P value < 0.05 is shown in bold.